GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Net Current Asset Value

BG Medicine (BG Medicine) Net Current Asset Value

: $-0.19 (As of Dec. 2015)
View and export this data going back to 2011. Start your Free Trial

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

BG Medicine's net current asset value per share for the quarter that ended in Dec. 2015 was $-0.19.

The historical rank and industry rank for BG Medicine's Net Current Asset Value or its related term are showing as below:

BGMD's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.705
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

BG Medicine Net Current Asset Value Historical Data

The historical data trend for BG Medicine's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Net Current Asset Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.03 -0.07 -0.23 0.02 -0.19

BG Medicine Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
Net Current Asset Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 -0.10 -0.30 -0.13 -0.19

Competitive Comparison

For the Medical Instruments & Supplies subindustry, BG Medicine's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BG Medicine Price-to-Net-Current-Asset-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, BG Medicine's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where BG Medicine's Price-to-Net-Current-Asset-Value falls into.



BG Medicine Net Current Asset Value Calculation

BG Medicine's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2015 is calculated as

Net Current Asset Value Per Share(A: Dec. 2015 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.951-4.109-0-0)/11.3195
=-0.19

BG Medicine's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2015 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2015 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.951-4.109-0-0)/11.3195
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BG Medicine  (OTCPK:BGMD) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


BG Medicine Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of BG Medicine's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BG Medicine (BG Medicine) Business Description

Traded in Other Exchanges
N/A
Address
303 Wyman Street, Suite 300, Waltham, MA, USA, 02451
BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Executives
Jeffrey R Luber director 100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos director 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox director ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc. 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp 10 percent owner C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp 10 percent owner ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr 10 percent owner
Flagship Ventures Fund 2007, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel director 320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r. director C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines